A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) in Saudi Arabia has entered a five-year partnership with the ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Researchers conducted a cohort study to try to characterize long-term treatment-related adverse effects and complications in ...

A bladder ultrasound is a noninvasive imaging technique used to check for abnormalities in the urinary bladder. It involves ...

Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...

Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing ...

Though they may seem like something from the future, these five cancer vaccines are available now. Here are details about who ...